

(FILE 'HOME' ENTERED AT 13:06:57 ON 20 JUL 2007)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOTECHDS, SCISEARCH, BIOSIS' ENTERED AT
13:07:25 ON 20 JUL 2007

L1 69 S L762P OR L550S OR L587S OR L984P OR L552S OR L763P
L2 42 DUP REM L1 (27 DUPLICATES REMOVED)
L3 2 S L1 AND (mRNA EXPRESSION)
L4 42 S L1 AND (AMPLIFICATION OR PCR OR HYBRIDIZATION OR LCR OR SDA O
L5 31 DUP REM L4 (11 DUPLICATES REMOVED)

=> d ti 15 1-31

L5 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
TI Sequences of human lung cancer markers and uses in diagnosis and
monitoring the progression of lung cancer

L5 ANSWER 2 OF 31 BIOTECHDS COPYRIGHT 2007 THE THOMSON CORP. on STN
TI In vitro diagnosing a predisposition to Long QT Syndrome or full-blown
Long QT Syndrome, comprises the detection in a DNA sample of a group of
mutations in KVLQT1, KCNH2 and SCN5A genes;
gene mutation identification using polymerase chain reaction and
direct sequencing for disease diagnosis

L5 ANSWER 3 OF 31 MEDLINE on STN DUPLICATE 2
TI Multigene real-time PCR detection of circulating tumor cells in
peripheral blood of lung cancer patients.

L5 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Immunogenic polypeptides, polynucleotides, antibodies and
antigen-presenting cells expressing them for diagnosis and therapy of lung
cancer

L5 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the
therapy and diagnosis of lung cancer

L5 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the
therapy and diagnosis of lung cancer

L5 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI nucleotide sequences of human lung cancer genes and methods for diagnosis
and monitoring the progression of lung cancer

L5 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the
therapy and diagnosis of lung cancer

L5 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor proteins, polynucleotides and antibodies for lung cancer
therapy and diagnosis

L5 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the
therapy and diagnosis of lung cancer

L5 ANSWER 11 OF 31 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
TI Detection of circulating tumor cells in peripheral blood of lung cancer
patients using a multiplex real-time RT-PCR assay for
L762P, L550S, L587S, and L984P.

L5 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
TI Human nucleic acid and expressed protein compositions and methods for the

therapy and diagnosis of lung cancer

L5 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung cancer antigens and cDNAs encoding them and their diagnostic, prophylactic and therapeutic uses

L5 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung cancer antigens and cDNAs encoding them and their diagnostic prophylactic and therapeutic uses

L5 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung carcinoma-derived polypeptides, polynucleotides, probes and primers, and antibodies for cancer therapy and diagnosis

L5 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor proteins, polynucleotides and antibodies for therapy and diagnosis of lung cancer

L5 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor polypeptides, polynucleotides, and antibodies for therapy and diagnosis of lung cancer

L5 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Expressed sequence profiles and their use for the therapy and diagnosis of human lung cancer

L5 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human nucleic acid and expressed protein compositions and methods for the therapy and diagnosis of lung cancer

L5 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor associated proteins and cDNAs and compositions and methods for therapy and diagnosis of lung cancer

L5 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Expressed sequence profiles and their use for the therapy and diagnosis of human lung cancer

L5 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Differentially expressed sequences and proteins for use in the therapy and

diagnosis of human lung cancer

L5 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor-specific antigen, chimeric antigens, polynucleotides, and
antibodies for therapy and diagnosis of lung cancer

L5 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
TI Lung tumor proteins, polynucleotides and antibodies for therapy and
diagnosis of lung cancer

L5 ANSWER 31 OF 31 MEDLINE on STN DUPLICATE 4
TI L552S, an alternatively spliced isoform of XAGE-1, is
over-expressed in lung adenocarcinoma.

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed

for L762P or L550S or L587S or L984P or L552S OR

Limits Preview/Index History Clipboard Details

The following terms were not found: L762P, L984P, L763P.

See [Details](#).Display 20 7Review: 0

Items 1 - 7 of 7

One page.

1: [Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H.](#) [Related Articles](#), [Links](#)
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Heart Rhythm. 2007 May;4(5):603-7. Epub 2007 Jan 18.
 PMID: 17467628 [PubMed - in process]

2: [Hayes DC, Sechrist H, Bangur CS, Wang T, Zhang X, Harlan D, Goodman GE, Houghton RL, Persing DH, Zehentner BK.](#) [Related Articles](#), [Links](#)
Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients.
Anticancer Res. 2006 Mar-Apr;26(2B):1567-75.
 PMID: 16619573 [PubMed - indexed for MEDLINE]

3: [Watanabe Y, LePage S, Elliott M, Sechrist H, Tanaka T, Kawahara M, Matsumura A, Hosoe S, Ogawara M, Okada M, Repasky B, Sleath P, Wang T, Henderson R.](#) [Related Articles](#), [Links](#)
Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer.
Cancer Immun. 2006 Feb 10;6:3.
 PMID: 16468707 [PubMed - indexed for MEDLINE]

4: [Fodstad H, Swan H, Laitinen P, Piippo K, Paavonen K, Viitasalo M, Toivonen L, Kontula K.](#) [Related Articles](#), [Links](#)
Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland.
Ann Med. 2004;36 Suppl 1:53-63.
 PMID: 15176425 [PubMed - indexed for MEDLINE]

5: [Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, Reed SG.](#) [Related Articles](#), [Links](#)
L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma.
Oncogene. 2001 Nov 22;20(53):7699-709.
 PMID: 11753648 [PubMed - indexed for MEDLINE]

6: [Piippo K, Laitinen P, Swan H, Toivonen L, Viitasalo M, Pasternack M, Paavonen K, Chapman H, Wann KT, Hirvela E, Sajantila A, Kontula K.](#) [Related Articles](#), [Links](#)
Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns.
J Am Coll Cardiol. 2000 Jun;35(7):1919-25.
 PMID: 10841244 [PubMed - indexed for MEDLINE]

7: [Giannoukos G, Silverstein AM, Pratt WB, Simons SS Jr.](#) [Related Articles](#), [Links](#)



The seven amino acids (547-553) of rat glucocorticoid receptor required for steroid and hsp90 binding contain a functionally independent LXXLL motif that is critical for steroid binding.

J Biol Chem. 1999 Dec 17;274(51):36527-36.

PMID: 10593951 [PubMed - indexed for MEDLINE]

One page.

Display [Summary](#)

Show 20 Pub Date Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

<!--StartFragment-->ABU66467
ID ABU66467 standard; protein; 236 AA.
XX
AC ABU66467;
XX
DT 22-MAY-2003 (first entry)
XX
DE Lung cancer therapy and diagnosis associated protein #91. ~~XX~~
XX
KW Lung cancer; cytostatic; vaccine; gene therapy; cancer.
XX
OS Homo sapiens. 
XX
PN US2002172952-A1.
XX
PD 21-NOV-2002.
XX
PF 10-JUL-2001; 2001US-00902941.
XX
PR 30-JUN-1999; 99US-00346492.
PR 15-OCT-1999; 99US-00419356.
PR 17-DEC-1999; 99US-00466867.
PR 30-DEC-1999; 99US-00476300.
PR 06-MAR-2000; 2000US-00519642.
PR 22-MAR-2000; 2000US-00533077.
PR 10-APR-2000; 2000US-00546259.
PR 27-APR-2000; 2000US-00560406.
PR 05-JUN-2000; 2000US-00589184.
PR 11-JUL-2000; 2000US-00614124.
PR 29-AUG-2000; 2000US-00651563.
PR 08-SEP-2000; 2000US-00658824.
PR 26-SEP-2000; 2000US-00671325.
PR 06-OCT-2000; 2000US-00677419.
PR 30-OCT-2000; 2000US-00702705.
PR 13-DEC-2000; 2000US-00736457.
PR 03-MAY-2001; 2001US-00849626.
XX
PA (CORI-) CORIXA CORP.
XX
PI Henderson RA, Wang T, Watanabe Y, Johnson JC, Retter MW;
PI Durham M, Carter D, Fanger GR, Vedvick TS, Bangur CS, Mcnabb A;
XX
DR WPI; 2003-328427/31.
XX
PT New polynucleotide, useful for preparing a composition for treating or
PT inhibiting development of cancer, e.g. lung cancer.
XX
PS Example 9; SEQID NO 1871; 82pp; English.
XX
CC The invention describes an isolated polynucleotide comprising one of 32
CC sequences, complement or degenerate variants of them. The polynucleotide
CC is useful for preparing a composition e.g. a vaccine or for gene therapy,
CC for treating or inhibiting development of cancer, e.g. lung cancer. This
CC sequence represents a polypeptide associated with the compositions and
CC methods for the therapy and diagnosis of lung cancer
XX
SQ Sequence 236 AA;

Query Match 100.0%; Score 1201; DB 6; Length 236;
Best Local Similarity 100.0%; Pred. No. 8.3e-111;
Matches 236; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESSAKMESGGAGQQPQPQPQQPFLPPAACFFATAAAAAAAAAAQSQQQQQQQQ 60
Db 1 MESSAKMESGGAGQQPQPQPQQPFLPPAACFFATAAAAAAAAAAQSQQQQQQQQ 60

Qy 61 QQAPQLRPAADGQPSSGGHKSAPKQVKRQRSSPELMRCKRRLNFSGFGYSLPQQQPAAV 120
Db 61 QQAPQLRPAADGQPSSGGHKSAPKQVKRQRSSPELMRCKRRLNFSGFGYSLPQQQPAAV 120

Qy 121 ARRNERERNRVKLVNLGFATLREHVPNGAANKMSKVETLRSAVEYIRALQQLLDEHDAV 180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 121 ARRNERERNRVKLVNLGFATLREHVPNGAANKMSKVETLRSAVEYIRALQQLLDEHDAV 180

Qy 181 SAAFQAGVLSPTISPNSNDLNSMAGSPVSSYSSDEGSYDPLSPEEQELLDFTNWF 236
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 181 SAAFQAGVLSPTISPNSNDLNSMAGSPVSSYSSDEGSYDPLSPEEQELLDFTNWF 236

<!--EndFragment-->

<!--StartFragment-->-895-828-453
; Sequence 453, Application US/09895828
; Patent No. US20020099012A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: McNeill, Patricia D.
; APPLICANT: Watanabe, Yoshihiro
; APPLICANT: Carter, Darrick
; APPLICANT: Henderson, Robert A.
; APPLICANT: Kalos, Michael D.
; TITLE OF INVENTION: COMPOSITIONS AND DIAGNOSIS OF
; TITLE OF INVENTION: AND DIAGNOSIS OF
; FILE REFERENCE: 210121.539
; CURRENT APPLICATION NUMBER: US/09/895828
; CURRENT FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: FastSEQ for Windows Version 1.0
; SEQ ID NO 453
; LENGTH: 2257
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-895-828-453

126

Db 601 AATTAATGATGTTATTAAAGAAATCAACAAGGCAGTAATTAGTAAATATAAAATCCTACA 660
Qy 661 TCAGCCAAAAAGTCTATGAATTCTGTGACCAGAAATCTCTATCACAGATTATTGATGA 720
Db 661 TCAGCCAAAAAGTCTATGAATTCTGTGACCAGAAATCTCTATCACAGATTATTGATGA 720
Qy 721 AGAAACGAAGGATACCAAAAGGTCGTTATTTATAGTGGAGCTGACATAAAGGAGTCAC 780
Db 721 AGAAACGAAGGATACCAAAAGGTCGTTATTTATAGTGGAGCTGACATAAAGGAGTCAC 780
Qy 781 AACTTGAAAGCTGACAAGAAGTTCACGTGTTACTGAATATTTACGACACTGCCGGAG 840
Db 781 AACTTGAAAGCTGACAAGAAGTTCACGTGTTACTGAATATTTACGACACTGCCGGAG 840
Qy 841 GCTATCAGAGGTCCGAGGGGGAGGACTTACTCGTTATGTTATAACCTGAGTCCCTGTGA 900
Db 841 GCTATCAGAGGTCCGAGGGGGAGGACTTACTCGTTATGTTATAACCTGAGTCCCTGTGA 900
Qy 901 ACTTTGAACATACCAACAGGGTATAGACTATAGAGGCTATTCTATAATTTCTTATAT 960
Db 901 ACTTTGAACATACCAACAGGGTATAGACTATAGAGGCTATTCTATAATTTCTTATAT 960
Qy 961 ATAATTTTTTAACCTTTAATCTTTGTTCCCTTTTTTTGAGACAGGATCT 1020
Db 961 ATAATTTTTTAACCTTTAATCTTTGTTCCCTTTTTTTGAGACAGGATCT 1020
Qy 1021 TGCTTGTCAACCAGGGCTTGCTTCACGCAGGCTAGAGTGCAGTGGCGAAACATG 1080
Db 1021 TGCTTGTCAACCAGGGCTTGCTTCACGCAGGCTAGAGTGCAGTGGCGAAACATG 1080
Qy 1081 GCTCACTGCAGCCTAACCTCCCAGGCTCAAGTGATCCTCCACCTCAGCCCCCTGAATG 1140
Db 1081 GCTCACTGCAGCCTAACCTCCCAGGCTCAAGTGATCCTCCACCTCAGCCCCCTGAATG 1140
Qy 1141 GCTGGACTACAAGCGTGCGCCACCATGCCTGGCTAATTTGTATTTTGAGAGATG 1200
Db 1141 GCTGGACTACAAGCGTGCGCCACCATGCCTGGCTAATTTGTATTTTGAGAGATG 1200
Qy 1201 GGGTTTCACCATGTTGCCTAGGCTGGCTTGAGCTCCTGAGCTAAACAATCCACCCCTCC 1260
Db 1201 GGGTTTCACCATGTTGCCTAGGCTGGCTTGAGCTCCTGAGCTAAACAATCCACCCCTCC 1260
Qy 1261 TCAGCCTCCAAAGTGCTGGATTACAGGCTTGAGCCACCACACCTGACCTATTCTGTT 1320
Db 1261 TCAGCCTCCAAAGTGCTGGATTACAGGCTTGAGCCACCACACCTGACCTATTCTGTT 1320
Qy 1321 TCTTATAAAAATAAAACTTTTGATAAGCTTATTCTTGTTTTTCTTTCTTT 1380
Db 1321 TCTTATAAAAATAAAACTTTTGATAAGCTTATTCTTGTTTTTCTTTCTTT 1380
Qy 1381 TTTTTTTTCGAGACTCCATCTCAGAAAAAAAGAAAAAGACTGGGTACAGATGTGA 1440
Db 1381 TTTTTTTTCGAGACTCCATCTCAGAAAAAAAGAAAAAGACTGGGTACAGATGTGA 1440
Qy 1441 TATTGGAAGAAAAGATCAAGCTGATGAGTTAGGATAACCCAGGCCCTTGGACTAAAG 1500
Db 1441 TATTGGAAGAAAAGATCAAGCTGATGAGTTAGGATAACCCAGGCCCTTGGACTAAAG 1500
Qy 1501 ATCACTAGTGTCTAAATTCCATCGATGGCATTCTAGTCTATAGTAAACTCCTGGAAGC 1560
Db 1501 ATCACTAGTGTCTAAATTCCATCGATGGCATTCTAGTCTATAGTAAACTCCTGGAAGC 1560
Qy 1561 TGGATTGGAGACAGTTATCATCTGATTATTGGCTTCTGTATAGTCCTAGGGAGCA 1620
Db 1561 TGGATTGGAGACAGTTATCATCTGATTATTGGCTTCTGTATAGTCCTAGGGAGCA 1620
Qy 1621 GCTTACCTGAAATGCATTTAGTGTACACCAGTCTGAAACTCAACCTGTAATGAAAGTG 1680
Db 1621 GCTTACCTGAAATGCATTTAGTGTACACCAGTCTGAAACTCAACCTGTAATGAAAGTG 1680

Qy 1681 TAATAAATGTACATTGAGTTGATGTGATAATGTGATATAAAGAAATATATATTGATC 1740
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1681 TAATAAATGTACATTGAGTTGATGTGATAATGTGATATAAAGAAATATATATTGATC 1740

Qy 1741 TTCCTATCTAGTCCTGTTCAGAGCTCCTAAACCCCTGTAATTCCAAAGTGATGGAG 1800
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1741 TTCCTATCTAGTCCTGTTCAGAGCTCCTAAACCCCTGTAATTCCAAAGTGATGGAG 1800

Qy 1801 TACATTTGTTCTAGTATTGGTCTTGACCCAGTCCTGACACAAAGCTCCTAAAT 1860
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1801 TACATTTGTTCTAGTATTGGTCTTGACCCAGTCCTGACACAAAGCTCCTAAAT 1860

Qy 1861 TCCTTAAATTCCCAGTGATAGGAGAATTTTGTCTAATGAGGTCACTCTGATGGG 1920
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1861 TCCTTAAATTCCCAGTGATAGGAGAATTTTGTCTAATGAGGTCACTCTGATGGG 1920

Qy 1921 CACCTGGATAACTCAGGATGGGGCTGCTCACAAAGACCACATCATGATTGAAAGTTCA 1980
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1921 CACCTGGATAACTCAGGATGGGGCTGCTCACAAAGACCACATCATGATTGAAAGTTCA 1980

Qy 1981 AACTTCAGTCTCCACCTCCAGAGAGGGGAGAGGGGCTGGAGATTGTGTCAATAATCC 2040
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1981 AACTTCAGTCTCCACCTCCAGAGAGGGGAGAGGGGCTGGAGATTGTGTCAATAATCC 2040

Qy 2041 ATCAGGCCTATGTCAACAAGACATAATCCGTTAACTATGGAGTTCAGGGAGCTTCAGGGT 2100
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2041 ATCAGGCCTATGTCAACAAGACATAATCCGTTAACTATGGAGTTCAGGGAGCTTCAGGGT 2100

Qy 2101 TGGCAACATTTGATGTGCCAGGAAGGTGACGCACTCCAGCTTATGAAGTCAGCAAGT 2160
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2101 TGGCAACATTTGATGTGCCAGGAAGGTGACGCACTCCAGCTTATGAAGTCAGCAAGT 2160

Qy 2161 CCTGTGCTCAGGATGCTTYTGGACCTTGCCCCAGGTACCCCTCATGTGGCTGTTCA 2220
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2161 CCTGTGCTCAGGATGCTTYTGGACCTTGCCCCAGGTACCCCTCATGTGGCTGTTCA 2220

Qy 2221 TCTGTATCCTTGAGTAGCCTAAATAAACTGTTA 2257
||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2221 TCTGTATCCTTGAGTAGCCTAAATAAACTGTTA 2257

<!--EndFragment-->

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, July 20, 2007

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L1	(L762P or L550S or L587S or L984P or L552S OR L763P)	3823
<input type="checkbox"/>	L2	L1 and (multiplex near PCR)	2
<input type="checkbox"/>	L3	L1 and (real-time PCR)	48
<input type="checkbox"/>	L4	L1 and gene expression	117
<input type="checkbox"/>	L5	L4 and (cancer near marker)	6
<input type="checkbox"/>	L6	L4 and cancer	104
<input type="checkbox"/>	L7	L6 and predetermined cut off	40
<input type="checkbox"/>	L8	L7 and (hybridization or amplification)	40
<input type="checkbox"/>	L9	20020052329 or 20020168637 or 20030103994 or 20020172952 or 2002017669 or 20020099012	13
<input type="checkbox"/>	L10	L9 and multiplex	0
<input type="checkbox"/>	L11	L10 and real time	0
<input type="checkbox"/>	L12	L9 and real time	6
<input type="checkbox"/>	L13	L9 and multiple\$	6

END OF SEARCH HISTORY

<!--StartFragment-->RESULT 5

ABU66397

ID , ABU66397 standard; protein; 200 AA.

XX

AC ABU66397;

XX

DT 22-MAY-2003 (first entry)

XX

DE Lung cancer therapyand diagnosis associated protein #21.

XX

KW Lung cancer; cytostatic; vaccine; gene therapy; cancer.

XX

OS Homo sapiens.

XX

PN US2002172952-A1.

XX

PD 21-NOV-2002.

XX

PF 10-JUL-2001; 2001US-00902941.

XX

PR 30-JUN-1999; 99US-00346492.

PR 15-OCT-1999; 99US-00419356.

PR 17-DEC-1999; 99US-00466867.

PR 30-DEC-1999; 99US-00476300.

PR 06-MAR-2000; 2000US-00519642.

PR 22-MAR-2000; 2000US-00533077.

PR 10-APR-2000; 2000US-00546259.

PR 27-APR-2000; 2000US-00560406.

PR 05-JUN-2000; 2000US-00589184.

PR 11-JUL-2000; 2000US-00614124.

PR 29-AUG-2000; 2000US-00651563.

PR 08-SEP-2000; 2000US-00658824.

PR 26-SEP-2000; 2000US-00671325.

PR 06-OCT-2000; 2000US-00677419.

PR 30-OCT-2000; 2000US-00702705.

PR 13-DEC-2000; 2000US-00736457.

PR 03-MAY-2001; 2001US-00849626.

XX

PA (CORI-) CORIXA CORP.

XX

PI Henderson RA, Wang T, Watanabe Y, Johnson JC, Retter MW;

PI Durham M, Carter D, Fanger GR, Vedvick TS, Bangur CS, Mcnabb A;

XX

DR WPI; 2003-328427/31.

XX

PT New polynucleotide, useful for preparing a composition for treating or
PT inhibiting development of cancer, e.g. lung cancer.

XX

PS Example 1; SEQ ID NO 789; 82pp; English.

XX

CC The invention describes an isolated polynucleotide comprising one of 32
CC sequences, complement or degenerate variants of them. The polynucleotide
CC is useful for preparing a composition e.g. a vaccine or for gene therapy,
CC for treating or inhibiting development of cancer, e.g. lung cancer. This
CC sequence represents a polypeptide associated with the compositions and
CC methods for the therapy and diagnosis of lung cancer

XX

SQ Sequence 200 AA;

Query Match 100.0%; Score 1066; DB 6; Length 200;

Best Local Similarity 100.0%; Pred. No. 1e-90;

Matches 200; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAKGDPKKPKGKMSAYAFFVQTCREEHKKKNPEVPVNFAEFSKKCSERWKTMSGKEKSKF 60
Db 1 MAKGDPKKPKGKMSAYAFFVQTCREEHKKKNPEVPVNFAEFSKKCSERWKTMSGKEKSKF 60

Qy 61 DEMAKADKVRYDREMKDYGPAKGKDKDPNAPKRPPSGFFLFCSEFRPKIKSTNPGISI 120
Db 1 DEMAKADKVRYDREMKDYGPAKGKDKDPNAPKRPPSGFFLFCSEFRPKIKSTNPGISI 120

6

<!--StartFragment-->Homo sapiens.

XX
PN US2003064947-A1.

XX
PD 03-APR-2003.

XX
PF 30-NOV-2001; 2001US-00007700.

XX
PR 18-MAR-1998; 98US-00040802.

PR 27-JUL-1998; 98US-00123912.

PR 22-DEC-1998; 98US-00221107.

PR 02-APR-1999; 99US-00285479.

PR 17-DEC-1999; 99US-00466396.

PR 30-DEC-1999; 99US-00476496.

PR 10-JAN-2000; 2000US-00480884.

PR 22-FEB-2000; 2000US-00510376.

PR 04-APR-2000; 2000US-00542615.

PR 28-JUN-2000; 2000US-00606421.

PR 02-AUG-2000; 2000US-00630940.

PR 21-AUG-2000; 2000US-00643597.

PR 15-SEP-2000; 2000US-00662786.

PR 09-OCT-2000; 2000US-00685696.

PR 12-DEC-2000; 2000US-00735705.

PR 07-MAY-2001; 2001US-00850716.

PR 28-JUN-2001; 2001US-00897778.

XX
PA (CORI-) CORIXA CORP.

XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;

PI Mcneill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;

PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;

XX
DR WPI; 2003-540798/51.

DR N-PSDB; ADA28250.

XX
PT New isolated polynucleotides and polypeptides useful for diagnosing,

PT preventing and/or treating cancer, particularly lung cancer.

XX
PS Example 3; Page 160-162; 296pp; English.

XX
CC The invention describes isolated polynucleotides and polypeptides useful

CC for diagnosing, preventing and/or treating cancer, particularly lung

CC cancer. A new isolated polynucleotide comprises: any of the 22 fully

CC defined nucleotide sequences (e.g. 1012, 900 or 2773 bp) given in the

CC specification; complements of the nucleotide sequences cited above; at

CC least 10 contiguous residues of the nucleotide sequences cited above; a

CC sequence that hybridise to any of the nucleotide sequences under highly

CC stringent conditions; a sequence that is at least 75 or 90% identical to

CC the above nucleotide sequences; or degenerate variants of the above

CC nucleotide sequences. The composition and methods are useful in

CC diagnosing, preventing and/or treating cancer, particularly lung cancer,

CC in gene therapy and in vaccines. This is the amino acid sequence encoded

CC by a human lung tumour cDNA isolated from a lung squamous cell carcinoma

CC that may be useful in the diagnosis and treatment of lung cancer and

CC other disorders.

XX
SQ Sequence 943 AA;

Query Match 100.0%; Score 4942; DB 7; Length 943;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 943; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTQRSTIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLIAINPQVPENQNLISN 60

Db 1 MTQRSTIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLIAINPQVPENQNLISN 60

Qy 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120

Db 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120

Qy 121 GDDPYTLQYRGCGKEGKYIHFTPFLNDNLTAGYGSGRVFVHEWAHLRWGVFDEYNND 180
Db 121 GDDPYTLQYRGCGKEGKYIHFTPFLNDNLTAGYGSGRVFVHEWAHLRWGVFDEYNND 180
Qy 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240
Db 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240
Qy 241 MFMQSLSSVVEFCNASTHNQEAPNLQNQMCSLRSAWDVITDSADFHHSPMNGTELPPPP 300
Db 241 MFMQSLSSVVEFCNASTHNQEAPNLQNQMCSLRSAWDVITDSADFHHSPMNGTELPPPP 300
Qy 301 TFSLVEAGDKVVCLVDVSSKMAEADRLQLQQAAEFYLMQIVEIHTFVGIAFDSKGEI 360
Db 301 TFSLVEAGDKVVCLVDVSSKMAEADRLQLQQAAEFYLMQIVEIHTFVGIAFDSKGEI 360
Qy 361 RAQLHQINSNDDRKLVSYLPPTVSAKTDISICSGLKKGFEVVEKLNGKAYGSVMIIVTS 420
Db 361 RAQLHQINSNDDRKLVSYLPPTVSAKTDISICSGLKKGFEVVEKLNGKAYGSVMIIVTS 420
Qy 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSRLTGGLKFFVVDISNSNSMIDAF 480
Db 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSRLTGGLKFFVVDISNSNSMIDAF 480
Qy 481 SRISSGTGDIFQQHQIQLESTGENVKPHQLKNTVTDNTVGNDTMFLVTWQASGPPEIIL 540
Db 481 SRISSGTGDIFQQHQIQLESTGENVKPHQLKNTVTDNTVGNDTMFLVTWQASGPPEIIL 540
Qy 541 FDPDGRKYYTNNFITNLTFRTASLWIPGTAKPGHWTYTLNNNTHSLQALKVTVTSRASNS 600
Db 541 FDPDGRKYYTNNFITNLTFRTASLWIPGTAKPGHWTYTLNNNTHSLQALKVTVTSRASNS 600
Qy 601 AVPPATVEAFVERDSLHFPHPMIYANVKQGFYPILNATVTATVEPETGDPVTLRLDDG 660
Db 601 AVPPATVEAFVERDSLHFPHPMIYANVKQGFYPILNATVTATVEPETGDPVTLRLDDG 660
Qy 661 AGADVIKNDGIYSRYFFSFAANGRYSKLVHVNHSPSISTPAHSIPGSHAMYVPGYTANGN 720
Db 661 AGADVIKNDGIYSRYFFSFAANGRYSKLVHVNHSPSISTPAHSIPGSHAMYVPGYTANGN 720
Qy 721 IQMNAPRKSVGRNEERKGFSRVSSGGFSVLGVPGPHPDVFPPCKIIDLEAVKVEEE 780
Db 721 IQMNAPRKSVGRNEERKGFSRVSSGGFSVLGVPGPHPDVFPPCKIIDLEAVKVEEE 780
Qy 781 LTLSWTAPGEDFDQQQATSYEIRMSKSLQNIQDDFNNAILVNTSKRNPQQAGIREIFTFS 840
Db 781 LTLSWTAPGEDFDQQQATSYEIRMSKSLQNIQDDFNNAILVNTSKRNPQQAGIREIFTFS 840
Qy 841 PQISTNGPEHQPNGETHESHRIYVAIRAMDRNSLQSAVSNIAQAPLFIPPNSDPVPARDY 900
Db 841 PQISTNGPEHQPNGETHESHRIYVAIRAMDRNSLQSAVSNIAQAPLFIPPNSDPVPARDY 900
Qy 901 LILKGVLTAMGLIGIICLIVVTHHTLSRKKRADKKENGTKLL 943
Db 901 LILKGVLTAMGLIGIICLIVVTHHTLSRKKRADKKENGTKLL 943

<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-09-643-597-161
; Sequence 161, Application US/09643597
; Patent No. 6426072
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Fan, Liqun
; APPLICANT: Kalos, Michael D.
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Hosken, Nancy
; APPLICANT: Fanger, Gary R.
; APPLICANT: Li, Samuel X.
; APPLICANT: Wang, Aijun
; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Henderson, Robert A.
; APPLICANT: McNeill, Patricia D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; TITLE OF INVENTION: AND DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 210121.455C11
; CURRENT APPLICATION NUMBER: US/09/643,597
; CURRENT FILING DATE: 2000-08-21
; NUMBER OF SEQ ID NOS: 369
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 161
; LENGTH: 943
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-643-597-161

Query Match 100.0%; Score 4942; DB 2; Length 943;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 943; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTQRSIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLLIAINPQVPENQNLISN 60
Db 1 MTQRSIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLLIAINPQVPENQNLISN 60

Qy 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120
Db 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120

Qy 121 GDDPYTLQYRGCGKEGKYIHFTPNFLNDNLTAGYGSRGRVFVHEWAHLRWGVFDEYNND 180
Db 121 GDDPYTLQYRGCGKEGKYIHFTPNFLNDNLTAGYGSRGRVFVHEWAHLRWGVFDEYNND 180

Qy 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240
Db 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240

Qy 241 MFMQLSSVVEFCNASTHNQEAPNLQNMCSLRSADWITDSADFHSFPMNGTELPPPP 300
Db 241 MFMQLSSVVEFCNASTHNQEAPNLQNMCSLRSADWITDSADFHSFPMNGTELPPPP 300

Qy 301 TFSLVEAGDKVVCLVDVSSKMAEADRLLQLQQAEFYLMQIVEIHTFVGIASFDSKGEI 360
Db 301 TFSLVEAGDKVVCLVDVSSKMAEADRLLQLQQAEFYLMQIVEIHTFVGIASFDSKGEI 360

Qy 361 RAQLHQINSNDDRKLVSYLPPTVSAKTDISICSGLKGFEVVEKLNGKAYGSVMIIVTS 420
Db 361 RAQLHQINSNDDRKLVSYLPPTVSAKTDISICSGLKGFEVVEKLNGKAYGSVMIIVTS 420

Qy 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSLRTGGLKFFVVDISNSNSMIDAF 480
Db 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSLRTGGLKFFVVDISNSNSMIDAF 480

Qy 481 SRISSGTGDIFFQQHQIQLESTGENVKPHQLKNTVTVDNTVGNDTMFLVTWQASGPPEIIL 540
Db 481 SRISSGTGDIFFQQHQIQLESTGENVKPHQLKNTVTVDNTVGNDTMFLVTWQASGPPEIIL 540

Qy 541 FDPDGRKYYTNNFITNLTFRTASLWIPGTAKPGHWTYTLNNNTHSLQALKVTVTSRASNS 600
|||
Db 541 FDPDGRKYYTNNFITNLTFRTASLWIPGTAKPGHWTYTLNNNTHSLQALKVTVTSRASNS 600

Qy 601 AVPPATVEAFVERDSLHFPHPVMIYANVKQGFYPILNATVTATVEPETGDPVTLRLDDG 660
|||
Db 601 AVPPATVEAFVERDSLHFPHPVMIYANVKQGFYPILNATVTATVEPETGDPVTLRLDDG 660

Qy 661 AGADVIKNDGIYSRYFFSFAANGRYSLKVHVNHSPSISTPAHSIPGSHAMYVPGYTANGN 720
|||
Db 661 AGADVIKNDGIYSRYFFSFAANGRYSLKVHVNHSPSISTPAHSIPGSHAMYVPGYTANGN 720

Qy 721 IQMNAPRKSVRNEEERKGFSRVSSGGSFSVLGVAGPHPDVFPPCKIIDLEAVKVEEE 780
|||
Db 721 IQMNAPRKSVRNEEERKGFSRVSSGGSFSVLGVAGPHPDVFPPCKIIDLEAVKVEEE 780

Qy 781 LTLSWTAPGEDFDQGQATSYEIRMSKSLQNIQDDFNNAILVNTSKRNPQQAGIREIFTFS 840
|||
Db 781 LTLSWTAPGEDFDQGQATSYEIRMSKSLQNIQDDFNNAILVNTSKRNPQQAGIREIFTFS 840

Qy 841 PQISTNGPEHQPNGETHESRIYVAIRAMDRNSLQSAVSNIAQAPLFIPPNSDPVPARDY 900
|||
Db 841 PQISTNGPEHQPNGETHESRIYVAIRAMDRNSLQSAVSNIAQAPLFIPPNSDPVPARDY 900

Qy 901 LILKGVLTAMGLIGIICLIIIVVTHHTLSRKKRADKKENGTKLL 943
|||
Db 901 LILKGVLTAMGLIGIICLIIIVVTHHTLSRKKRADKKENGTKLL 943

<!--EndFragment-->

<!--StartFragment-->RESULT 1

US-09-735-705-161

; Sequence 161, Application US/09735705

; Patent No. US20020052329A1

77

GENERAL INFORMATION:

; APPLICANT: Wang, Tongtong

; APPLICANT: Fan, Liqun

; APPLICANT: Kalos, Michael D.

; APPLICANT: Bangur, Chaitanya S.

; APPLICANT: Hosken, Nancy

; APPLICANT: Fanger, Gary R.

; APPLICANT: Li, Samuel X.

; APPLICANT: Wang, Aijun

; APPLICANT: Skeiky, Yasir A.W.

; APPLICANT: Henderson, Robert A.

; APPLICANT: McNeill, Patricia D.

; APPLICANT: Fanger, Neil

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY

; TITLE OF INVENTION: AND DIAGNOSIS OF LUNG CANCER

; FILE REFERENCE: 210121.455C14

; CURRENT APPLICATION NUMBER: US/09/735,705

; CURRENT FILING DATE: 2000-12-12

; NUMBER OF SEQ ID NOS: 419

; SOFTWARE: FastSEQ for Windows Version 3.0

; SEQ ID NO 161

; LENGTH: 943

; TYPE: PRT

; ORGANISM: Homo sapien

US-09-735-705-161

Query Match 100.0%; Score 4942; DB 3; Length 943;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 943; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTQRSIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLLIAINPQVPENQNLISN 60
|||

Db 1 MTQRSIAGPICNLKFVTLLVALSSELPFLGAGVQLQDNGYNGLLIAINPQVPENQNLISN 60

Qy 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120
|||

Db 61 IKEMITEASFYLFNATKRRVFFRNIKILIPATWKANNNSKIKQESYEKANVIVTDWYGAH 120

Qy 121 GDDPYTLQYRGCGKEGKYIHFTPFLNDNLTAGYGSGRVFVHEWAHLRGVFDEYNND 180
|||

Db 121 GDDPYTLQYRGCGKEGKYIHFTPFLNDNLTAGYGSGRVFVHEWAHLRGVFDEYNND 180

Qy 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240
|||

Db 181 KPFYINGQNQIKVTRCSSDITGIFVCEKGPCPQENCIISKLFKEGCTFIYNSTQNATASI 240

Qy 241 MFMQSLSSVVEFCNASTHNEAPNLQNMCSLRSAWDVITDSADFHHSPMNGTELPPPP 300
|||

Db 241 MFMQSLSSVVEFCNASTHNEAPNLQNMCSLRSAWDVITDSADFHHSPMNGTELPPPP 300

Qy 301 TFSLVEAGDKVVCLVDVSSKMAEADRLLQLQQAEFYLMQIVEIHTFVGIAFSFDKGEI 360
|||

Db 301 TFSLVEAGDKVVCLVDVSSKMAEADRLLQLQQAEFYLMQIVEIHTFVGIAFSFDKGEI 360

Qy 361 RAQLHQINSNDRKLLVSYLPPTVSAKTDISICSGLKKGFVVEKLNKGAYGSVMILVTS 420
|||

Db 361 RAQLHQINSNDRKLLVSYLPPTVSAKTDISICSGLKKGFVVEKLNKGAYGSVMILVTS 420

Qy 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSLRTGGLKFFVVDISNSNSMIDAF 480
|||

Db 421 GDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSLRTGGLKFFVVDISNSNSMIDAF 480

Qy 481 SRISSGTGDIFFQQHQIQLESTGENVKPHQLKNTVTDNTVGNDTMFLVTWQASGPPEIIL 540
|||

Db 481 SRISSGTGDIFFQQHQIQLESTGENVKPHQLKNTVTDNTVGNDTMFLVTWQASGPPEIIL 540

Qy 541 FDPDGRKYYTNNFITNLTFR~~T~~ASLWIPGTAKPGHWTYTLNNTH~~S~~LQALKVT~~V~~TSRASNS 600
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 541 FDPDGRKYYTNNFITNLTFR~~T~~ASLWIPGTAKPGHWTYTLNNTH~~S~~LQALKVT~~V~~TSRASNS 600
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 601 AVPPATVEAFVERDSLHF~~P~~HPVMIYANVKQGF~~P~~ILNATVTATVEPETGDPVTLRLDDG 660
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 601 AVPPATVEAFVERDSLHF~~P~~HPVMIYANVKQGF~~P~~ILNATVTATVEPETGDPVTLRLDDG 660
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 661 AGADVIKNDGIYSRYFFSFAANGRYS~~I~~KVHVNH~~S~~PSISTPAHSIPGSHAMYVPGYTANGN 720
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 661 AGADVIKNDGIYSRYFFSFAANGRYS~~I~~KVHVNH~~S~~PSISTPAHSIPGSHAMYVPGYTANGN 720
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 721 IQMNAPRK~~S~~VRNEEERK~~W~~GFSRVSSGGSF~~S~~V~~L~~GPAGPHPDVF~~P~~CKIIDLEAVKVEEE 780
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 721 IQMNAPRK~~S~~VRNEEERK~~W~~GFSRVSSGGSF~~S~~V~~L~~GPAGPHPDVF~~P~~CKIIDLEAVKVEEE 780
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 781 LTLSWTAPGEDFDQGQATSYEIRMSK~~S~~LQNIQDDFN~~N~~AILV~~N~~TSKRNPQQAGIREIFTFS 840
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 781 LTLSWTAPGEDFDQGQATSYEIRMSK~~S~~LQNIQDDFN~~N~~AILV~~N~~TSKRNPQQAGIREIFTFS 840
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 841 PQISTNGPEHQPNGETHESHRIYVAIRAMDR~~N~~SLQSAVSNIAQAPLF~~I~~PPNSDPV~~P~~ARDY 900
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 841 PQISTNGPEHQPNGETHESHRIYVAIRAMDR~~N~~SLQSAVSNIAQAPLF~~I~~PPNSDPV~~P~~ARDY 900
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 901 LILKGVL~~T~~AMGLIGIICL~~I~~IVVTH~~H~~TL~~S~~RKKRADKKENG~~T~~KLL 943
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 901 LILKGVL~~T~~AMGLIGIICL~~I~~IVVTH~~H~~TL~~S~~RKKRADKKENG~~T~~KLL 943
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

<!--EndFragment-->

WEST Search History

DATE: Friday, July 20, 2007

<u>Hide?</u>	<u>Set</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L1	(L762P or L550S or L587S or L984P or L552S OR L763P)	3823
<input type="checkbox"/>	L2	L1 and (multiplex near PCR)	2
<input type="checkbox"/>	L3	I1 and (real-time PCR)	48
<input type="checkbox"/>	L4	I1 and gene expression	117
<input type="checkbox"/>	L5	L4 and (cancer near marker)	6
<input type="checkbox"/>	L6	I4 and cancer	104
<input type="checkbox"/>	L7	L6 and predetermined cut off	40
<input type="checkbox"/>	L8	L7 and (hybridization or amplification)	40
<input type="checkbox"/>	L9	20020052329 or 20020168637 or 20030103994 or 20020172952 or 2002017669 or 20020099012	13
<input type="checkbox"/>	L10	L9 and multiplex	0
<input type="checkbox"/>	L11	L10 and real time	0
<input type="checkbox"/>	L12	L9 and real time	6
<input type="checkbox"/>	L13	L9 and multiple\$	6

END OF SEARCH HISTORY

WEST Search History

DATE: Friday, July 20, 2007

<u>Hide?</u>	<u>Set</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L1	(L762P or L550S or L587S or L984P or L552S OR L763P)	3823
<input type="checkbox"/>	L2	L1 and (multiplex near PCR)	2
<input type="checkbox"/>	L3	I1 and (real-time PCR)	48
<input type="checkbox"/>	L4	I1 and gene expression	117
<input type="checkbox"/>	L5	L4 and (cancer near marker)	6
<input type="checkbox"/>	L6	I4 and cancer	104
<input type="checkbox"/>	L7	L6 and predetermined cut off	40
<input type="checkbox"/>	L8	L7 and (hybridization or amplification)	40
<input type="checkbox"/>	L9	20020052329 or 20020168637 or 20030103994 or 20020172952 or 2002017669 or 20020099012	13
<input type="checkbox"/>	L10	L9 and multiplex	0
<input type="checkbox"/>	L11	L10 and real time	0
<input type="checkbox"/>	L12	L9 and real time	6
<input type="checkbox"/>	L13	L9 and multiple\$	6

END OF SEARCH HISTORY